Pulmonary Embolism Treatment Xarelto® (Rivaroxaban) Recommended For EU Approval

Rivaroxaban offers the first oral single-drug solution for the treatment of PE and long-term prevention of DVT and PE. Decision of European Commisson on approval expected before year-end. Bayer HealthCare's oral anticoagulant Xarelto® (rivaroxaban) has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of pulmonary embolism (PE) and the prevention of recurrent deep vein thrombosis (DVT) and PE in adults. The decision of the European Commission on the approval is expected before the year-end... via Health News from Medical News Today Read More Here..